Sign Out
UserName
Profession Email
Profession Email
|
Contraindications
Hypersensitivity to ceftazidime and other cephalosporins, or history of severe hypersensitivity to any other type of β-lactam antibacterial agents (e.g. penicillins, monobactams, carbapenems).
|
|
Special Precautions
Patient with history of gastrointestinal disease, particularly colitis; history of seizure disorder. Renal impairment. Neonates, children, and elderly. Pregnancy and lactation. Monitoring Parameters Perform culture and susceptibility tests; consult local institutional recommendations before treatment initiation due to antibiotic resistance risks. Monitor renal function. Assess for signs and symptoms of anaphylaxis during 1st dose; nephrotoxicity, neurotoxicity, severe or bloody diarrhoea.
|
|
Adverse Reactions
Significant: Diarrhoea, increased INR; overgrowth of non-susceptible organisms (prolonged use).
Blood and lymphatic system disorders: Eosinophilia, thrombocytosis.
General disorders and administration site conditions: Phlebitis or thrombophlebitis (IV); pain or inflammation (IM).
Investigations: Transient elevations in ALT, AST, lactate dehydrogenase, gamma-glutamyl transferase and alkaline phosphatase.
Skin and subcutaneous tissue disorders: Maculopapular or urticarial rash.
Potentially Fatal: Severe hypersensitivity reactions; antibacterial agent-associated colitis and pseudomembranous colitis; haemolytic anaemia. |
|
Drug Interactions
Concurrent administration of nephrotoxic agents such as aminoglycosides or potent diuretics (e.g. furosemide) may adversely affect renal function. Antagonistic effect with chloramphenicol. Ceftazidime may affect the gut flora, resulting in decreased
reabsorption of estrogen and reduced efficacy of combined oral contraceptives.
|
|
CIMS Class
|
|
ATC Classification
J01DD02 - ceftazidime ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
|
